Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway
Xue Yang,Ying Feng,Yao Liu,Xieqiong Ye,Xiaomin Ji,Le Sun,Fangyuan Gao,Qun Zhang,Yuxin Li,Bingbing Zhu,XianBo Wang
DOI: https://doi.org/10.1016/j.phymed.2021.153575
IF: 6.656
2021-07-01
Phytomedicine
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p><strong>:</strong> Hepatocellular carcinoma (HCC) is a common malignant tumor with limited treatment options. Conventional antitumor therapy combined with traditional Chinese medicine (TCM) to limit tumor progression has gradually become the focus of complementary and alternative therapies for HCC treatment. The Fuzheng Jiedu Xiaoji formulation (FZJDXJ) alleviates the clinical symptoms of patients and inhibits tumor progression, but its curative effect still requires extensive clinical research and mechanistic analysis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p><strong>:</strong> To explore the effectiveness of FZJDXJ in HCC patients and investigate its biological function and mechanism underlying anticancer therapy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p><strong>:</strong> This randomized controlled clinical trial enrolled 291 HCC patients receiving transcatheter arterial chemoembolization (TACE) therapy; patients received either FZJDXJ combined with standard treatment, or standard treatment alone, for 48 weeks. Statistical analyses were performed according to survival time at the end of the trial. The main constituents of the FZJDXJ extracts were identified and evaluated using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) and molecular docking. The antitumor effects of FZJDXJ and its specific biological mechanism of action were studied.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p><strong>:</strong> After 48 weeks of treatment, one-year overall survival (OS) and progression-free survival (PFS) were significantly different between the two groups. Co-administration of FZJDXJ and TACE prolonged the OS of HCC patients, especially in BCLC A or B stage. FZJDXJ and TACE treatment effectively extended the PFS of patients, especially in the BCLC B stage. HPLC-MS/MS identified 1619 active constituents of FZJDXJ, including <em>formononetin, chlorogenic acid</em> (CGA), <em>caffeic acid, luteolin, gallic acid, diosgenin, ergosterol, endoperoxide, and lupeol,</em> which may function through the AKT/CyclinD1/p21/p27 pathways. Through molecular docking, CGA and <em>gallic acid</em> could effectively combine with Thr308, an important phosphorylation site of AKT1. FZJDXJ inhibited tumor growth in nude mice. <em>In vitro,</em> FZJDXJ-mediated serum inhibited the proliferation, migration, and invasion of liver cancer cells, and promoted cell apoptosis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p><strong>:</strong> Clinically, FZJDXJ combined with TACE therapy significantly prolonged OS and PFS and reduced the mortality rate of HCC patients. Mechanistically, FZJDXJ effectively inhibited the proliferation and migration of liver cancer cells through the modulation of the AKT/CyclinD1/p21/p27 pathways, and may be a promising TCM drug for anti-HCC therapy.</p>
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences